No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Express News | MannKind Corp: Expects to Ship Product for Cipla Ltd. by End of 2025
CDSCO Approves Afrezza (Insulin Human) Inhalation Powder in India
MannKind Corporation's (NASDAQ:MNKD) Institutional Investors Lost 3.9% Last Week but Have Benefitted From Longer-term Gains
Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7
Oppenheimer Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $12
IntegriChain Revenue Optimization Experts to Speak at Informa's Pharma/BioTech GTN Summit